## biotechne

### **Recombinant Human Plasma alpha-L-**Fucosidase/FUCA2 His-tag

**R**Dsystems

Catalog Number: 11405-GH

ט	Е	S	C	RI	Р
~	-			-	

DESCRIPTION	
Source	Chinese Hamster Ovary cell line, CHO-derived human Plasma alpha-L-Fucosidase/FUCA2 protein His29-Ile467 with an N-terminal 6-His tag Accession # Q9BTY2.2
N-terminal Sequence Analysis	His
Predicted Molecular Mass	52 kDa

SPECIFICATIONS		
SDS-PAGE	52-58 kDa, under reducing conditions.	
Activity	Measured by its ability to cleave a fluorogenic substrate 4-methylumbelliferyl-α-L-fucopyranoside. The specific activity is >550 pmol/min/μg, as measured under the described conditions.	
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.	
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.	
Formulation	Supplied as a 0.2 µm filtered solution in Tris and NaCI. See Certificate of Analysis for details.	

Activity Assay Protocol	
Materials	<ul> <li>Assay Buffer: 50 mM Sodium Acetate, pH 4.5</li> <li>Recombinant Human Plasma alpha-L-Fucosidase/FUCA2 His-tag (rhFUCA2) (Catalog # 11405-GH)</li> <li>Substrate: 4-Methylumbelliferyl-alpha -L-fucopyranoside, 50 mM stock in DMSO</li> <li>Black 96 Well Plate</li> <li>Plate Reader with Fluorescence Read Capability</li> </ul>
Assay	<ol> <li>Dilute rhFUCA2 to 5 μg/mL in Assay Buffer.</li> <li>Dilute Substrate to 1.6 mM in Assay Buffer.</li> <li>Load into a plate 50 μL of 5 μg/mL rhFUCA2, and start the reaction by adding 50 μL of 1.6 mM Substrate. Include a Substrate Blank containing 50 μL of Assay Buffer and 50 μL of 1.6 mM Substrate.</li> <li>Read plate at excitation and emission wavelengths of 365 nm and 445 nm, respectively, in kinetic mode for 5 minutes.</li> <li>Calculate specific activity:</li> </ol>
	Specific Activity (pmol/min/μg) = Adjusted V <sub>max</sub> * (RFU/min) x Conversion Factor** (pmol/RFU) amount of enzyme (μg)

\*Adjusted for Substrate Blank

	**Derived using calibration standard 4-Methylumbelliferone (4-MU)
Final Assay Conditions	Per Well: • rhFUCA2: 0.25 μg • Substrate: 0.8 mM

PREPARATION AND STORAGE	
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
	<ul> <li>6 months from date of receipt, -20 to -70 °C as supplied.</li> </ul>
	<ul> <li>3 months, -20 to -70 °C under sterile conditions after opening.</li> </ul>

Rev. 9/19/2023 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449

# biotechne

**R**Dsystems

## Recombinant Human Plasma alpha-L-Fucosidase/FUCA2 His-tag

Catalog Number: 11405-GH



#### BACKGROUND

Plasma alpha-L-Fucosidase, also known as FucA2 (FUCA2), is an enzyme responsible for hydrolyzing alpha-L-fucose (1). FUCA2 and its isoform FUCA1 are human fucosidases of the glycoside hydrolase family 29A (2). Whereas FUCA2 is secreted and localized to plasma, FUCA1 is expressed in cellular tissues in the lysosome (3). The mature FUCA2 enzyme exists in the native state as a homotetramer and contains a highly conserved eukaryotic alpha fucosidase catalytic N-terminal barrel structure. In comparison to FUCA1, FUCA2 may not contain a catalytic residue in the sixth beta strand of the barrel structure which may suggest differing substrate specificity or catalytic mechanism (2). FUCA2 has specificity for fucose linked via  $\alpha$ -1,2,  $\alpha$ -1,3,  $\alpha$ -1,4, or  $\alpha$ -1,6 to the reducing end of glycans (4). As fucosylated glycoconjugates play numerous roles in biological events such as development, apoptosis, and the immune response, fucosylated glycoconjugates are involved in the pathology of inflammation, cancer, and cystic fibrosis (5-8). FUCA2 has been implicated to play a role in several human diseases; FUCA2 was found to be upregulated in 24 tumor types and was associated with negative outcomes for several of the cancer types (9). In addition, FUCA2 was found to play a major role in bacterial adhesion in H. pylori-induced diseases like gastric cancer and duodenal ulcers (10). Consequently, FUCA2 may be of use in both diagnostic and therapeutic research.

#### References:

- 1. Van Elsen, A. et al. (1983) Human Genetics 64:235.
- 2. Intra, J. et al. (2007) Gene 392:34
- 3. Fukushima, H. et al. (1985) Proc. Natl. Acad. Sci. USA 82:1262.
- 4. Johnson, S. et al. (1991) Comp Biochem Physiol B. 99:479.
- 5. Hiraishi, K. et al. (1993) Glycobiology 3:381.
- 6. Solter, D. and Knowles, B.B. (1978) Proc. Natl. Acad. Sci. USA 75:5565.
- 7. Becker, D.J. and Lowe, J.B. (2003) Glycobiology 13:41R.
- 8. Liu, T.W. et al. (2009) Proc. Natl. Acad. Sci. USA 106:14581.
- 9. Zhong, A. et al. (2021) Front. Immunol. 12:758648
- 10. Liu, T.W. et al. (2009) Proc Natl Acad Sci. USA 105:14581.

### Rev. 9/19/2023 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449